May 15, 2013
Global Green, Inc. Announces Conclusion of Final Study Conducted for USDA Approval of Salmonella Vaccine
Tallahassee, Fla – May 15, 2012 – Global Green, Inc. (OTCBB:GOGC) announced today that the Company has received the final report on the model Efficacy Study conducted on the Company’s patented vaccine, Salmogenics, to be used to protect poultry from Salmonella bacteria. This study, conducted by AHPharma, an independent food safety and animal health research firm, is an important step towards receiving USDA approval for Salmogenics.
The Study was performed using 3,036 chickens, specifically broilers. Those chickens injected in ovo (in the egg before the chick is hatched) with Salmogenics showed a significant reduction in Salmonella bacteria.
The study reports that the “Salmogenics Vaccine appears to provide enough protection against all strains of Salmonella tested.” Clearly, Salmogenics provided protection in broilers against the spread of Salmonella. The conclusion of the study reports that reducing Salmonella in chickens prior to them being processed and sold to the public is critical in reducing Salmonella levels.
“Our patented Salmogenics Vaccine is in the fourth and final phase required for USDA approval. The final report on the data in the Study conducted by AHPharma is very encouraging and will be forwarded to the USDA,” commented Dr. Mehran Ghazvini, Chairman and CEO, Global Green, Inc.
Salmogenics Utilizes Unique Application
When Salmonella is discovered in the flock during the processing stage, the costs to eradicate the disease are staggering. Salmogenics is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken. The vaccine reduces levels of Salmonella in the flock and reduces the risk of Salmonella contamination in the processing plant.
Leading Poultry Industry Expert Confirms Significance of Vaccine
The historic approach for Salmonella control ignores chicken live growing practices and attempts to completely eliminate Salmonella and other foodborne bacteria during final processing. A Salmonella vaccine addressing vigorous strains that are hard to destroy is important,” commented James McNaughton, PhD, leading independent poultry research expert.
About Global Green, Inc.
Global Green, Inc. is a green bio-pharmaceutical company committed to identifying technology platforms and commercializing vaccines that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards without the use of mercury. For more information, visitwww.globalgreeninc.com.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties which include, among others, the inherent uncertainties associated with smaller reporting companies including, without limitation, other risks detailed from time to time in the Company’s periodic reports filed with the SEC.